Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 7;17(6):753.
doi: 10.3390/pharmaceutics17060753.

Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review

Brooke G Musburger  1 , Maria Gonzalez Echeandia  1 , Elias L Suskind  2 , David L Suskind  1 , Hengqi Betty Zheng  1 , Dominique Mark  3
Affiliations
Review

Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review

Brooke G Musburger et al. Pharmaceutics. .

Abstract

Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the complex interaction of genetic predisposition and environmental triggers, both which contribute to esophageal inflammation. Current societal guidelines recommend the use of proton pump inhibitors, topical steroids, and dietary interventions such as elimination diets as first-line treatments, however, the recent approval of Dupliumab has provided an additional therapeutic avenue. There are a number of investigational biologic agents targeting other immune pathways which are making their way through the pipeline of pharmacologic options in treating this chronic disorder.

Keywords: EGID; EoE; eosinophilic esophagitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Biologic agent target sites of action.
See this image and copyright information in PMC

References

    1. Lucendo A.J., Molina-Infante J., Arias Á., von Arnim U., Bredenoord A.J., Bussmann C., Amil Dias J., Bove M., González-Cervera J., Larsson H., et al. Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur. Gastroenterol. J. 2017;5:335–358. doi: 10.1177/2050640616689525. - DOI - PMC - PubMed
    1. Dhar A., Haboubi H.N., Attwood S.E., Auth M.K.H., Dunn J.M., Sweis R., Morris D., Epstein J., Novelli M.R., Hunter H., et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022;71:1459–1487. doi: 10.1136/gutjnl-2022-327326. - DOI - PMC - PubMed
    1. Kumar M., Sweis R., Wong T. Eosinophilic oesophagitis: Investigations and management. Postgrad. Med. J. 2014;90:273–281. doi: 10.1136/postgradmedj-2013-131843. - DOI - PubMed
    1. Barni S., Arasi S., Mastrorilli C., Pecoraro L., Giovannini M., Mori F., Liotti L., Saretta F., Castagnoli R., Caminiti L., et al. Pediatric eosinophilic esophagitis: A review for the clinician. Ital. J. Pediatr. 2021;47:230. doi: 10.1186/s13052-021-01178-2. - DOI - PMC - PubMed
    1. Ryu S., Lee K.H., Tizaoui K., Terrazzino S., Cargnin S., Effenberger M., Shin J.I., Kronbichler A. Pathogenesis of eosinophilic esophagitis: A comprehensive review of the genetic and molecular aspects. Int. J. Mol. Sci. 2020;21:7253. doi: 10.3390/ijms21197253. - DOI - PMC - PubMed

LinkOut - more resources